Last reviewed · How we verify
Hib-MenAC mixed with Tritanrix™-HepB
This combination vaccine stimulates immune responses against Haemophilus influenzae type b, Neisseria meningitidis serogroups A and C, diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis through antigen presentation.
This combination vaccine stimulates immune responses against Haemophilus influenzae type b, Neisseria meningitidis serogroups A and C, diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis through antigen presentation. Used for Prevention of Haemophilus influenzae type b infection in infants and children, Prevention of meningococcal disease (serogroups A and C) in infants and children, Prevention of diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis in infants and children.
At a glance
| Generic name | Hib-MenAC mixed with Tritanrix™-HepB |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Hib-MenAC provides conjugate vaccines against Haemophilus influenzae type b and meningococcal serogroups A and C, while Tritanrix-HepB is a pentavalent vaccine covering diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliomyelitis. When mixed, the combination elicits humoral and cellular immune responses to prevent these infectious diseases in infants and young children.
Approved indications
- Prevention of Haemophilus influenzae type b infection in infants and children
- Prevention of meningococcal disease (serogroups A and C) in infants and children
- Prevention of diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
- Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants (PHASE3)
- Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib-MenAC mixed with Tritanrix™-HepB CI brief — competitive landscape report
- Hib-MenAC mixed with Tritanrix™-HepB updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI